Logo image of CTKB

CYTEK BIOSCIENCES INC (CTKB) Stock Fundamental Analysis

NASDAQ:CTKB - Nasdaq - US23285D1090 - Common Stock - Currency: USD

3.34  -0.06 (-1.76%)

After market: 3.34 0 (0%)

Fundamental Rating

4

CTKB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for CTKB as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CTKB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CTKB had negative earnings in the past year.
In the past year CTKB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CTKB reported negative net income in multiple years.
Of the past 5 years CTKB 4 years had a positive operating cash flow.
CTKB Yearly Net Income VS EBIT VS OCF VS FCFCTKB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

CTKB has a Return On Assets of -2.33%. This is in the better half of the industry: CTKB outperforms 63.64% of its industry peers.
Looking at the Return On Equity, with a value of -2.96%, CTKB is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
ROA -2.33%
ROE -2.96%
ROIC N/A
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
CTKB Yearly ROA, ROE, ROICCTKB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

CTKB's Gross Margin of 54.94% is fine compared to the rest of the industry. CTKB outperforms 67.27% of its industry peers.
CTKB's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CTKB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
CTKB Yearly Profit, Operating, Gross MarginsCTKB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTKB has less shares outstanding than it did 1 year ago.
CTKB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CTKB is higher compared to a year ago.
CTKB Yearly Shares OutstandingCTKB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CTKB Yearly Total Debt VS Total AssetsCTKB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 3.35 indicates that CTKB is not in any danger for bankruptcy at the moment.
CTKB has a Altman-Z score of 3.35. This is in the better half of the industry: CTKB outperforms 70.91% of its industry peers.
CTKB has a debt to FCF ratio of 0.28. This is a very positive value and a sign of high solvency as it would only need 0.28 years to pay back of all of its debts.
The Debt to FCF ratio of CTKB (0.28) is better than 92.73% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CTKB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CTKB is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.28
Altman-Z 3.35
ROIC/WACCN/A
WACC10.57%
CTKB Yearly LT Debt VS Equity VS FCFCTKB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 5.62 indicates that CTKB has no problem at all paying its short term obligations.
CTKB's Current ratio of 5.62 is fine compared to the rest of the industry. CTKB outperforms 76.36% of its industry peers.
CTKB has a Quick Ratio of 4.95. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
CTKB's Quick ratio of 4.95 is fine compared to the rest of the industry. CTKB outperforms 78.18% of its industry peers.
Industry RankSector Rank
Current Ratio 5.62
Quick Ratio 4.95
CTKB Yearly Current Assets VS Current LiabilitesCTKB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CTKB have decreased strongly by -8900.00% in the last year.
CTKB shows a decrease in Revenue. In the last year, the revenue decreased by -1.86%.
Measured over the past years, CTKB shows a very strong growth in Revenue. The Revenue has been growing by 28.19% on average per year.
EPS 1Y (TTM)-8900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-1.86%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%-7.59%

3.2 Future

CTKB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.72% yearly.
CTKB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.40% yearly.
EPS Next Y-140.72%
EPS Next 2Y-10.63%
EPS Next 3Y37.72%
EPS Next 5YN/A
Revenue Next Year-0.03%
Revenue Next 2Y4.18%
Revenue Next 3Y7.4%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CTKB Yearly Revenue VS EstimatesCTKB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CTKB Yearly EPS VS EstimatesCTKB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.05 -0.05 0.1 -0.1 0.15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CTKB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTKB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTKB Price Earnings VS Forward Price EarningsCTKB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CTKB is valued a bit cheaper than 76.36% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.4
EV/EBITDA N/A
CTKB Per share dataCTKB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

CTKB's earnings are expected to grow with 37.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.63%
EPS Next 3Y37.72%

More info and screens

0

5. Dividend

5.1 Amount

CTKB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTEK BIOSCIENCES INC

NASDAQ:CTKB (6/5/2025, 8:00:01 PM)

After market: 3.34 0 (0%)

3.34

-0.06 (-1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners60.89%
Inst Owner Change0.66%
Ins Owners8.85%
Ins Owner Change0.58%
Market Cap423.04M
Analysts76.67
Price Target6.83 (104.49%)
Short Float %4.04%
Short Ratio4.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.05%
Min EPS beat(2)-96.08%
Max EPS beat(2)31.98%
EPS beat(4)2
Avg EPS beat(4)-15.05%
Min EPS beat(4)-161.44%
Max EPS beat(4)165.36%
EPS beat(8)3
Avg EPS beat(8)103.04%
EPS beat(12)6
Avg EPS beat(12)76.91%
EPS beat(16)8
Avg EPS beat(16)70.04%
Revenue beat(2)0
Avg Revenue beat(2)-4.92%
Min Revenue beat(2)-5.11%
Max Revenue beat(2)-4.73%
Revenue beat(4)0
Avg Revenue beat(4)-4.49%
Min Revenue beat(4)-7.72%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-3.1%
Revenue beat(12)3
Avg Revenue beat(12)-5.19%
Revenue beat(16)7
Avg Revenue beat(16)-2.84%
PT rev (1m)0%
PT rev (3m)-16.25%
EPS NQ rev (1m)-35.71%
EPS NQ rev (3m)-58.33%
EPS NY rev (1m)-136%
EPS NY rev (3m)-5800%
Revenue NQ rev (1m)-3.81%
Revenue NQ rev (3m)-10.16%
Revenue NY rev (1m)-0.75%
Revenue NY rev (3m)-7.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.15
P/FCF 24.4
P/OCF 19.86
P/B 1.11
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)0.14
FCFY4.1%
OCF(TTM)0.17
OCFY5.03%
SpS1.56
BVpS3
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.33%
ROE -2.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.94%
FCFM 8.8%
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
F-Score6
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.28
Debt/EBITDA N/A
Cap/Depr 33.9%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.62
Quick Ratio 4.95
Altman-Z 3.35
F-Score6
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)161.41%
Cap/Depr(5y)218.84%
Cap/Sales(3y)3.46%
Cap/Sales(5y)3.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y-140.72%
EPS Next 2Y-10.63%
EPS Next 3Y37.72%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.86%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%-7.59%
Revenue Next Year-0.03%
Revenue Next 2Y4.18%
Revenue Next 3Y7.4%
Revenue Next 5YN/A
EBIT growth 1Y6.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year174.75%
EBIT Next 3Y48.44%
EBIT Next 5YN/A
FCF growth 1Y199.14%
FCF growth 3Y331.22%
FCF growth 5YN/A
OCF growth 1Y369.92%
OCF growth 3Y76.32%
OCF growth 5YN/A